From the protein craze to new clothing sizes: the impact of Ozempic and other weight-loss drugs is being felt in the retail sector. Consumers aren’t just eating less; above all, they’re shopping differently. New research shows that GLP-1 medication is even changing how often they visit brick-and-mortar stores.
Billions in revenue at risk
It’s now common knowledge that the rapid rise of GLP-1 medications is putting pressure on food companies: these drugs suppress appetite and, for many users, reduce cravings for high-calorie snacks and treats. That’s precisely where many large FMCG companies generate a significant portion of their revenue.
Europe - EN
België - NL
Nederland - NL
España - ES
France - FR


